C07K 16/2842
Against integrin beta1-subunit-containing molecules
Official title: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
C07K16/2842 (Against integrin beta1-subunit-containing molecules) appears on 237 US grants and 436 published applications in this corpus.
Search patents in C07K- Granted patents
- 237
- Published applications
- 436
- Assignees
- 208
- Inventors
- 713
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 10 |
| 2003 | 2 | 5 |
| 2004 | 0 | 9 |
| 2005 | 4 | 14 |
| 2006 | 1 | 16 |
| 2007 | 8 | 15 |
| 2008 | 7 | 17 |
| 2009 | 7 | 16 |
| 2010 | 14 | 33 |
| 2011 | 11 | 17 |
| 2012 | 9 | 19 |
| 2013 | 17 | 13 |
| 2014 | 11 | 23 |
| 2015 | 9 | 18 |
| 2016 | 12 | 21 |
| 2017 | 8 | 15 |
| 2018 | 13 | 13 |
| 2019 | 18 | 23 |
| 2020 | 8 | 19 |
| 2021 | 13 | 24 |
| 2022 | 11 | 18 |
| 2023 | 5 | 19 |
| 2024 | 10 | 25 |
| 2025 | 11 | 13 |
| 2026 | 3 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-VLA-4 antibodies15 Sep 2026US 12,734,236 B2Biogen MA Inc.
- Methods of treating inflammatory and autoimmune diseases with natalizumab21 Apr 2026US 12,607,638 B2Biogen MA Inc.
- Model-informed precision dosing systems for treatment of inflammatory bowel disease20 Jan 2026US 12,531,141 B2Children's Hospital Medical Center
- Antibodies against integrin alpha 11 beta 14 Nov 2025US 12,460,006 B2Momenta Pharmaceuticals, Inc.
- Nanobody based imaging and targeting of ECM in disease and development28 Oct 2025US 12,454,576 B2Children's Medical Center Corporation
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Compositions and methods involving integrin alpha3beta11 Oct 2026US 2026/0297198 A1149 Bio, LLC
- Anti-human integrin alpha3/Beta1 antibodies and methods of use therefor10 Sep 2026US 2026/0265382 A1Medabome, Inc.
- Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof20 Aug 2026US 2026/0240999 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Method of assessing risk of pml16 Jul 2026US 2026/0202418 A1Biogen MA Inc.
Most cited
By later US patents
- Frozen piercing implements and methods for piercing a substrate284US 8,784,385 B2The Invention Science Fund I, LLC · 2014
- Humanized antibodies against leukocyte adhesion molecule VLA-4161US 5,840,299 AAthena Neurosciences, Inc. · 1998
- Mutant antibody Fc domains and fusion proteins thereof95US 8,409,568 B2MedImmune, LLC · 2013
- Compositions and methods for modulating leukocyte adhesion to brain endothelial cells76US 6,033,665 AElan Pharmaceuticals, Inc. · 2000
- Recombinant anti-VLA-4 antibody molecules73US 6,602,503 B1Biogen, Inc. · 2003